Hendrik Fuchs

2.9k total citations
107 papers, 2.4k citations indexed

About

Hendrik Fuchs is a scholar working on Molecular Biology, Immunology and Biotechnology. According to data from OpenAlex, Hendrik Fuchs has authored 107 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Molecular Biology, 65 papers in Immunology and 22 papers in Biotechnology. Recurrent topics in Hendrik Fuchs's work include Toxin Mechanisms and Immunotoxins (61 papers), Natural product bioactivities and synthesis (22 papers) and Transgenic Plants and Applications (16 papers). Hendrik Fuchs is often cited by papers focused on Toxin Mechanisms and Immunotoxins (61 papers), Natural product bioactivities and synthesis (22 papers) and Transgenic Plants and Applications (16 papers). Hendrik Fuchs collaborates with scholars based in Germany, United States and United Kingdom. Hendrik Fuchs's co-authors include Christopher Bachran, Alexander Weng, Matthias F. Melzig, Mark Sutherland, R Tauber, Diana Bachran, Mayank Thakur, Roger Gilabert‐Oriol, Iring Heisler and Reinhard Geßner and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and The Journal of Cell Biology.

In The Last Decade

Hendrik Fuchs

104 papers receiving 2.3k citations

Peers

Hendrik Fuchs

IMMUN

BIOTE

RNMI

Jean‐Claude Michalski France

William C. Raschke United States

Katsuko Yamashita Japan

Noriko Takahashi Japan

Ernst Bause Germany

Oleg V. Kurnasov United States

Louis N. Gastinel France

Younghee Lee South Korea

Inkyu Hwang United States

Joop van den Heuvel Germany

Jean‐Claude Michalski France

Hendrik Fuchs

3.9k ×3.1

1.4k ×1.3

IMMUN

267 ×0.6

BIOTE

307 ×1.3

RNMI

242 ×1.1

Citations per year, relative to Hendrik Fuchs Hendrik Fuchs (= 1×) peers Jean‐Claude Michalski

Countries citing papers authored by Hendrik Fuchs

Since Specialization

Citations

This map shows the geographic impact of Hendrik Fuchs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hendrik Fuchs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hendrik Fuchs more than expected).

Fields of papers citing papers by Hendrik Fuchs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hendrik Fuchs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hendrik Fuchs. The network helps show where Hendrik Fuchs may publish in the future.

Co-authorship network of co-authors of Hendrik Fuchs

This figure shows the co-authorship network connecting the top 25 collaborators of Hendrik Fuchs. A scholar is included among the top collaborators of Hendrik Fuchs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hendrik Fuchs. Hendrik Fuchs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Konrad, Jerry Leung, January Weiner, et al.. (2025). Lung tissue-optimized gene editing in human cystic fibrosis models following topical application of lipid nanoparticles. Journal of Controlled Release. 385. 114053–114053.

Meier, Niklaus, et al.. (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. PharmacoEconomics - Open. 8(3). 373–387. 3 indexed citations

Koczurkiewicz, Paulina, Karolina Grabowska, Elżbieta Karnas, et al.. (2023). Saponin Fraction CIL1 from Lysimachia ciliata L. Enhances the Effect of a Targeted Toxin on Cancer Cells. Pharmaceutics. 15(5). 1350–1350. 2 indexed citations

Fischer, Alexandra, et al.. (2023). Synergistic Cytotoxicity of a Toxin Targeting the Epidermal Growth Factor Receptor and the Glycosylated Triterpenoid SO1861 in Prostate Cancer. Journal of Cancer. 14(16). 3039–3049. 1 indexed citations

Monaco, Gianni, et al.. (2023). Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861. Frontiers in Pharmacology. 14. 1211824–1211824. 3 indexed citations

Woith, Eric, et al.. (2021). Suicide nanoplasmids coding for ribosome-inactivating proteins. European Journal of Pharmaceutical Sciences. 170. 106107–106107. 5 indexed citations

Fischer, Alexandra, et al.. (2020). Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer. Toxins. 12(12). 753–753. 15 indexed citations

Gilabert‐Oriol, Roger, Sebastian G. B. Furness, Brett W. Stringer, et al.. (2017). Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma. Cancer Immunology Immunotherapy. 66(9). 1217–1228. 16 indexed citations

Gilabert‐Oriol, Roger, et al.. (2014). Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy. Current Pharmaceutical Design. 20(42). 6584–6643. 62 indexed citations

10.

Bachran, Christopher, et al.. (2014). Triterpenoid saponin augmention of saporin-based immunotoxin cytotoxicity for human leukaemia and lymphoma cells is partially immunospecific and target molecule dependent. Immunopharmacology and Immunotoxicology. 37(1). 42–55. 23 indexed citations

11.

Weng, Alexander, Mayank Thakur, Figen Beceren‐Braun, et al.. (2012). The toxin component of targeted anti‐tumor toxins determines their efficacy increase by saponins. Molecular Oncology. 6(3). 323–332. 39 indexed citations

12.

Fuchs, Hendrik, Diana Bachran, Alexander Weng, et al.. (2009). Saponins as Tool for Improved Targeted Tumor Therapies. Current Drug Targets. 10(2). 140–151. 64 indexed citations

13.

Bachran, Christopher, et al.. (2008). Chimeric toxins inhibit growth of primary oral squamous cell carcinoma cells. Cancer Biology & Therapy. 7(2). 237–242. 14 indexed citations

14.

Coelho, Vânia, Jens Dernedde, Hendrik Fuchs, et al.. (2008). Production of bifunctional single-chain antibody-based fusion proteins in Pichia pastoris supernatants. Bioprocess and Biosystems Engineering. 31(6). 559–568. 12 indexed citations

15.

Heisler, Iring, et al.. (2005). Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells. Journal of Controlled Release. 106(1-2). 123–137. 55 indexed citations

16.

Heisler, Iring, et al.. (2002). A Colorimetric Assay for the Quantitation of Free Adenine Applied to Determine the Enzymatic Activity of Ribosome-Inactivating Proteins. Analytical Biochemistry. 302(1). 114–122. 89 indexed citations

17.

Kaup, Matthias, et al.. (2002). Shedding of the Transferrin Receptor Is Mediated Constitutively by an Integral Membrane Metalloprotease Sensitive to Tumor Necrosis Factor α Protease Inhibitor-2. Journal of Biological Chemistry. 277(41). 38494–38502. 36 indexed citations

18.

Orberger, Georg, et al.. (2001). Structural and Functional Stability of the Mature Transferrin Receptor from Human Placenta. Archives of Biochemistry and Biophysics. 386(1). 79–88. 15 indexed citations

19.

Heisler, Iring, et al.. (2001). Development of a novel molecular adapter for the optimization of immunotoxins. Journal of Controlled Release. 74(1-3). 259–261. 16 indexed citations

20.

Fuchs, Hendrik, et al.. (1998). Human transferrin receptor is active and plasma membrane-targeted in yeast. FEMS Microbiology Letters. 160(1). 61–67. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact